Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple arm catheter replace risky neck lines for hard-stick patients?

NCT ID NCT06719869

Knowledge-focused Sponsor: Region Jönköping County Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study compares two types of catheters for patients whose veins are difficult to access: a standard central line (inserted into a large vein in the neck, chest, or groin) and a midline catheter (inserted into a vein in the upper arm). The goal is to see if it is practical to run a larger study on this question. Thirty adults with difficult IV access will be randomly assigned to one of the two devices, and researchers will track how well the study procedures work, including recruitment, adherence, and data collection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Midline intravenous catheter (PowerGlide Pro™ Midline Catheter)
What this could lead to
If successful, this pilot could pave the way for a larger trial that may show midline catheters are a safer, simpler option for patients with difficult veins.
What could go wrong
This is a very small pilot study (30 participants) testing feasibility, not effectiveness. It is too early to draw conclusions about which device is better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Jan 2025

Finished

Sep 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Age 18 and over * DIVA criterium fulfilled; * 2 attempts of venous access by 2 clinicians OR * No visible nor palpable veins OR * History of difficult venous access * 4 - 29 days of catheter dwell time anticipated as assessed by referring clinician. Exclusion Criteria: * Unable to speak Scandinavian * Cognitive Impairment * Is to receive hyperosmolar solutions (600 milliosmoles/L or above). * Is to receive chemotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Difficult intravenous access are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Difficult intravenous access

Contacts and locations

Locations

  • Länssjukhuset Ryhov

    Jönköping, Region Jönköping, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.